Charles Schwab
LRMR icon

Charles Schwab’s Larimar Therapeutics LRMR Stock Holding History

Charles Schwab’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$631K Buy
206,969
+61,627
+42% +$245K ﹤0.01% 3168
2026
Q1 		$654K Sell
145,342
-16,771
-10% -$67K ﹤0.01% 3024
2025
Q4 		$618K Hold
162,113
– – ﹤0.01% 3093
2025
Q3 		$524K Buy
162,113
+50,713
+46% +$190K ﹤0.01% 3161
2025
Q2 		$322K Buy
111,400
+10,943
+11% +$25.3K ﹤0.01% 3288
2025
Q1 		$216K Sell
100,457
-24,670
-20% -$78K ﹤0.01% 3248
2024
Q4 		$484K Hold
125,127
– – ﹤0.01% 3150
2024
Q3 		$820K Sell
125,127
-2,968
-2% -$23.9K ﹤0.01% 2983
2024
Q2 		$929K Buy
128,095
+45,086
+54% +$345K ﹤0.01% 2963
2024
Q1 		$630K Buy
83,009
+9,246
+13% +$72K ﹤0.01% 2940
2023
Q4 		$336K Hold
73,763
– – ﹤0.01% 3197
2023
Q3 		$291K Hold
73,763
– – ﹤0.01% 3222
2023
Q2 		$231K Buy
73,763
+58,626
+387% +$239K ﹤0.01% 3286
2023
Q1 		$68.6K Hold
15,137
– – ﹤0.01% 3299
2022
Q4 		$62.5K Buy
+15,137
New +$51.7K ﹤0.01% 3318
2019
Q2 		– Sell
-4,814
Closed -$159K – 3249
2019
Q1 		$159K Sell
4,814
-834
-15% -$42.8K ﹤0.01% 3056
2018
Q4 		$336K Hold
5,648
– – ﹤0.01% 2897
2018
Q3 		$793K Buy
5,648
+2,098
+59% +$255K ﹤0.01% 2695
2018
Q2 		$436K Buy
+3,550
New +$302K ﹤0.01% 2847
2017
Q2 		– Sell
-3,714
Closed -$208K – 3123
2017
Q1 		$208K Hold
3,714
– – ﹤0.01% 2923
2016
Q4 		$142K Hold
3,714
– – ﹤0.01% 3016
2016
Q3 		$148K Sell
3,714
-2,134
-36% -$96.9K ﹤0.01% 2972
2016
Q2 		$421K Buy
5,848
+3,875
+196% +$306K ﹤0.01% 2651
2016
Q1 		$159K Sell
1,973
-2,015
-51% -$159K ﹤0.01% 2942
2015
Q4 		$301K Sell
3,988
-428
-10% -$68.7K ﹤0.01% 2862
2015
Q3 		$1.69M Buy
4,416
+2,443
+124% +$1.1M ﹤0.01% 2159
2015
Q2 		$820K Buy
1,973
+1,056
+115% +$442K ﹤0.01% 2505
2015
Q1 		$436K Buy
917
+209
+30% +$99.2K ﹤0.01% 2675
2014
Q4 		$263K Buy
+708
New +$182K ﹤0.01% 2897

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Charles Schwab's LRMR Position: Q2 2026 in Review

Charles Schwab increased its Larimar Therapeutics (LRMR) stake by 42% in Q2 2026, buying an estimated $245K and bringing the position to 206,969 shares worth $631K. The position accounts for ﹤0.01% of the portfolio, ranked #3168.

Charles Schwab first reported a position in LRMR in Q4 2014 and has held it in 29 quarters since. The position peaked at $1.69M in Q3 2015. 162 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Charles Schwab held 206,969 shares of Larimar Therapeutics worth $631K as of Q2 2026.
  • Charles Schwab bought 61,627 Larimar Therapeutics shares in Q2 2026, an estimated $245K.
  • Larimar Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3168 holding.
  • Charles Schwab first reported a position in Larimar Therapeutics in Q4 2014 and has held it in 29 quarters since.
  • Charles Schwab's Larimar Therapeutics position peaked at $1.69M in Q3 2015.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.